The concurrent depletion of tumour cells and immunosuppressive cells via a monoclonal antibody targeting a common surface marker prevents tumours from acquiring resistance to therapies involving immune checkpoint blockade.
Nature Reviews Clinical Oncology – ALND can be safely omitted for patients with sentinel-node macrometastases
FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer.
Nature Reviews Clinical Oncology – T cell infiltration in the tumour microenvironment (TME) is a prerequisite for sustained antitumour immune responses. However, identifying predictive biomarkers…
Nature Reviews Clinical Oncology – The benefit of combining antiangiogenic agents with immune-checkpoint inhibitors has been demonstrated in pivotal phase III trials across different cancer…
Nature Reviews Clinical Oncology – Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer
Nature Reviews Clinical Oncology – Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer
On March 22, 2024, the Food and Drug Administration approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) for adult patients with FRα…
FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products
Nature Reviews Clinical Oncology – A new standard of care for advanced-stage urothelial carcinoma
